Clinical trials: First in Man Study to Evaluate Initial Safety
Paroxysmal Nocturnal Hemoglobinuria
To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of KP104 in healthy volunteers.
- Trial name
- NCT05490017
- Testing
- KP104
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Kira Pharmacenticals (US), LLC.
Healthy
A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single (part 1) and multiple ascending (part 2) oral doses of GLPG4399, in adult, healthy, male subjects.
- Trial name
- NCT04653467
- Testing
- GLPG4399 oral suspension, GLPG4399 capsules
- Where
- Canada
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Cognitive Disorders
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-D4010 in healthy male subjects following single or multiple ascending doses.
- Trial name
- NCT02575482
- Testing
- SUVN-D4010
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Healthy Volunteer
Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers
This study in healthy human volunteers will investigate the effects of a single dose (SAD) and multiple days of dosing (MAD) of WP1122 administered as an oral (PO) solution.
- Trial name
- NCT05195723
- Testing
- WP1122
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Moleculin Biotech, Inc.
Respiratory Syncytial Viruses, Respiratory Tract Infections
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers
The purpose of this study is to assess the safety and tolerability of intramuscular prime-boost regimens of Ad26.RSV.FA2 given either once or twice followed by Ad35.RSV.FA2 (human adenovirus-vectored vaccine candidate) in healthy…
- Trial name
- NCT02561871
- Testing
- Ad26.RSV.FA2, Ad35.RSV.FA2
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Healthy
A Study to Evaluate the Effects of a Single and Multiple Oral Doses of GLPG3121 in Adult, Healthy, Male Subjects
This study is a first-in-human, Phase I, randomized, double-blind, placebo controlled, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GLPG3121 after oral single ascending…
- Trial name
- NCT03899909
- Testing
- GLPG3121 SAD, GLPG3121 MAD
- Where
- Belgium
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Obstetric Labour, Premature, Premature Ejaculation
A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.
A study conducted on healthy volunteers to determine the safety, tolerability and affect on the human body by experimental drug GSK557296.
- Trial name
- NCT00549211
- Testing
- GSK557296
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants
This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4004280 in healthy adults.
- Trial name
- NCT05163522
- Testing
- VH4004280, Midazolam
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy Volunteers, Atopic Dermatitis
A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome
The study is divided in 3 parts, starting with the safety assessment of BPR277 ointment in Healthy volunteers (Part 1). If found to be well tolerated in Part 1, BPR277 ointment will be assessed in two different patients groups to…
- Conditions
- Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
- Trial name
- 3 (NCT01428297)
- Testing
- BPR277 ointment (controlled application), BPR277 ointment, BPR277
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis B
A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy volunteers and in chronic hepatitis B (CHB) patients after single and multiple doses.
- Trial name
- NCT05717686
- Testing
- AHB-137 injection
- Where
- 9 sites in United States, Hong Kong and 2 more
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AusperBio Therapeutics Inc.
Healthy Volunteers
First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-04427429 administered intravenously to healthy adult volunteers.
- Trial name
- NCT01011296
- Testing
- PF-04427429
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects
A dose-block randomized, double-blind, placebo-controlled, single and multiple ascending dose, first-in-human, phase 1 first in human clinical trial to evaluate the safety, tolerability, and pharmacokinetics after subcutaneous…
- Trial name
- NCT05701644
- Testing
- C1K 150mg, C1K 300mg, C1K 600mg
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Ensol Bioscience
Influenza
A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study
This randomized, double-blind, placebo-controlled, 4 part study will assess the safety, tolerability, pharmacokinetics and antiviral activity of orally administered AL-794 in healthy volunteers (HV).
- Trial name
- NCT02588521
- Testing
- AL-794
- Where
- United Kingdom
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Healthy
A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667
This study is a first-in-human, Phase I, randomized, double-blind, placebo-controlled, single-center, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of GLPG3667 after oral…
- Trial name
- NCT04097938
- Testing
- GLPG3667 oral suspension, GLPG3667 capsules
- Where
- Belgium
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Nonalcoholic Steatohepatitis
A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects
To evaluate the safety, tolerability, and immunogenicity of B1344 by single subcutaneous (s.c.) injection in healthy subjects
- Trial name
- NCT05655221
- Testing
- B1344
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Healthy
A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants
This study is the first clinical study with PF-07328948. The safety, tolerability, and plasma pharmacokinetics and pharmacodynamics of PF-07328948 after administration of escalating, single, oral doses will be evaluated.
- Trial name
- NCT05654181
- Testing
- PF-07328948
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cancer
Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers
The purpose of this study is to test the safety of a new drug and to look at how the drug is handled by your body. This is the first time the drug will be given to people, the drug has been safely given to animals over many days…
- Trial name
- FTIH (NCT00996671)
- Testing
- GSK2256098
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Health Participants
A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants
The purpose of this study is to investigate the safety and tolerability of BMS-986209 in healthy participants. The first-in-human study is designed in 3 parts that vary based on duration and food effect.
- Trial name
- NCT04154800
- Testing
- BMS-986209, Itraconazole, Diltiazem
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Participants
A First-In-Human Study of the Study Medicine, Called PF-07291177, in Healthy Adult Participants
The purpose of the study is to learn about the safety, tolerability (the extent to which side effects can be tolerated), and plasma pharmacokinetics (PK) (PK helps us understand how the drug is changed and eliminated from body…
- Trial name
- NCT05434091
- Testing
- PF-07291177
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-121 in Healthy Subjects
This is an open label, phase 1, "3+3", placebo-controlled dose escalating study of tolerability, safety, pharmacokinetics, pharmacodynamics and immunogenicity of a single subcutaneous injection of the novel monoclonal bispecific…
- Trial name
- NCT03103451
- Testing
- BCD-121
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Biocad